Elan reports "solid" start to 2012

UPDATE: Elan has reported a 17 per cent rise in revenues for the first quarter of the year and says opportunities in neurology are significant.

26th April, 2012
Elan's Kelly Martin

Elan has reported a 17 per cent rise in revenues for the first quarter of the year.

Revenues at the firm that focuses on neurological disorders totalled $288.4 million in the three months, Elan said.

Revenue from its multiple sclerosis drug Tysabri totalled $288.2 million, which was just ahead of expectations according to Bloomberg News.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago